<abstract xmlns="http://www.w3.org/1999/xhtml">

Heart failure (HF) is a major public health problem characterised by a high rate of hospitalisation and death. The risk is maximal for patients admitted with acute heart failure (AHF). New therapies with solid proof of mortality reduction in both groups of patients with reduced and preserved ejection fraction (EF) are now available (valsartan/sacubitril and SGLT2 inhibitors).
The purpose of this article is to review the main data available and to clarify the role of these new therapies in AHF. The precise moment of initiating these therapies is still a matter of debate. This paper presents the recommended criteria for clinical stability that the clinician could use in deciding to initiate therapy. There is a growing amount of evidence that initiating these therapies sooner provides more benefits to patients.
</abstract>

Heart failure (HF) is a major public health problem characterised by a high rate of hospitalisation and death. The risk is maximal for patients admitted with acute heart failure (AHF). New therapies with solid proof of mortality reduction in both groups of patients with reduced and preserved ejection fraction (EF) are now available (valsartan/sacubitril and SGLT2 inhibitors).
The purpose of this article is to review the main data available and to clarify the role of these new therapies in AHF. The precise moment of initiating these therapies is still a matter of debate. This paper presents the recommended criteria for clinical stability that the clinician could use in deciding to initiate therapy. There is a growing amount of evidence that initiating these therapies sooner provides more benefits to patients.

Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?

“Carol Davila” Medicine and Pharmacy University

Romanian Journal of Cardiology

This work is licensed under the Creative Commons Attribution 4.0 International License.

{"article-title":"Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?"}

Heart failure (HF) is a major public health problem characterised by a high rate of hospitalisation and death. The risk is maximal for patients admitted with...

Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?

Article Category: Review

Data publikacji: 31 gru 2022

Zakres stron: 167 - 173

DOI: https://doi.org/10.2478/rjc-2022-0035

Słowa kluczowe
Heart failure, Valsartan/Sacubitril, SGLT inhibitors

© 2022 Alexandru Cristian Nechita, published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?

Article Category: Review

Data publikacji: 31 gru 2022

Zakres stron: 167 - 173

DOI: https://doi.org/10.2478/rjc-2022-0035

Słowa kluczoweHeart failure, Valsartan/Sacubitril, SGLT inhibitors

© 2022 Alexandru Cristian Nechita, published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Słowa kluczowe
Heart failure, Valsartan/Sacubitril, SGLT inhibitors